We use compounded semaglutide and tirzepatide that can be precisely dosed and titrated to each patient's biology including microdosing protocols for patients who need the anti-inflammatory benefit without the aggressive appetite suppression that comes with standard dosing
When it comes to weight management, GLP-1s natural ability to reduce appetite and support blood sugar regulation can make it highly effective
Unlike larger proteins that undergo hepatic metabolism or receptor-mediated endocytosis for degradation, KLOW's primary clearance route is direct renal excretion
If you used expired semaglutide once, monitor your blood sugar levels closely if you have diabetes and watch for any unusual symptoms
Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide